In particular, concerning ibrutinib-resistant CLL associated with PLCG2 mutations, in vitro studies have shown that the inhibition of SYK and LYN, both necessary for the activation of PLCγ2 independently of BTK, can overcome sustained survival signaling [104]. This evidence concerns the gene PLCG2 and B-cell chronic lymphocytic leukemia.